Panzyga in CIDP Administered at Different Infusion Rates

Summary

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable form of peripheral neuropathy with suspected autoimmune cause. The current first-line treatment is IVIG (immune globulin), which is infused in a set regimen that requires 4-5 hours in a hospital day unit, taking up resources such as nursing time and hospital space. Chronic treatment is required in most cases.

Timeline

Start

2017-06-01

Primary completion

2018-12-15

Completion

2018-12-15

Drugs

Indications